Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
暂无分享,去创建一个
Y. Fujiwara | A. Stopeck | M. Lichinitser | G. Steger | J. Body | K. Tonkin | D. Yardley | A. Lipton | A. Braun | M. Viniegra | S. Jun | R. D. de Boer | R. Dansey | M. Fan | Q. Jiang
[1] D. Castellano,et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain , 2010, European journal of cancer care.
[2] J. Dungan. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis , 2010 .
[3] Robert J Griffin,et al. Mechanisms of bone metastases of breast cancer. , 2009, Endocrine-related cancer.
[4] X. Mariette,et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Major,et al. Effect of bisphosphonates on pain and quality of life in patients with bone metastases , 2009, Nature Clinical Practice Oncology.
[6] M. Falagas,et al. Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone , 2009, Oncology.
[7] H. Parnes,et al. Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents , 2009, Cancer investigation.
[8] T. Ruhstaller,et al. Bevacizumab-associated osteonecrosis of the jaw. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] R. Chlebowski,et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Gascón,et al. Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy , 2008, Clinical Cancer Research.
[11] J. Abrahm,et al. Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life". , 2008, JAMA.
[12] J. Abrahm,et al. Spinal Cord Compression in Patients With Advanced Metastatic Cancer , 2008 .
[13] M. Perazella,et al. Bisphosphonate nephrotoxicity. , 2008, Kidney international.
[14] W. Alexander,et al. American Society of Clinical Oncology , 2020, Definitions.
[15] X. Badia,et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence , 2008, Supportive Care in Cancer.
[16] P. Gascón,et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Cook,et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. , 2007, The oncologist.
[18] R. Coleman. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. , 2007, Clinical breast cancer.
[19] M. Neary,et al. The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid , 2007, Cancer.
[20] W. Rifkin. Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.
[21] M. Tabrizi,et al. Elimination mechanisms of therapeutic monoclonal antibodies. , 2006, Drug discovery today.
[22] M. Neary,et al. CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA) , 2005 .
[23] F. Saad,et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Y. Ohashi,et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Roodman. Mechanisms of bone metastasis. , 2004, Discovery medicine.
[26] J. Cauley,et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Beitz,et al. Renal failure with the use of zoledronic acid. , 2003, The New England journal of medicine.
[28] A. Howell,et al. Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.
[29] P. Fine,et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). , 2003, Kidney international.
[30] Yi Tsong,et al. Some fundamental issues with non‐inferiority testing in active controlled trials , 2002, Statistics in medicine.
[31] A. Howell,et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.
[32] R. Coleman. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.
[33] G. Hortobagyi,et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.
[34] G. Hortobagyi,et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[36] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[37] G. Hortobagyi,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.
[38] R. Gill,et al. Cox's regression model for counting processes: a large sample study : (preprint) , 1982 .